Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interleukin-1 Receptor-like protein (SIGIRR)
- Target
- SIGIRR
- Molecular classification
- Single immunoglobulin and toll-interleukin 1 receptor (TIR) domain-containing protein, Interleukin-1 receptor/toll-like receptor superfamily, Receptor
01
Overview
Interleukin-1 Receptor-like protein (SIGIRR), also known as TIR8 or IL-1R8, is a negative regulator of inflammation belonging to the interleukin-1 receptor/toll-like receptor superfamily. It inhibits signal transduction from multiple interleukin and toll-like receptors, suppressing downstream signaling pathways such as NF-κB and JNK. SIGIRR plays a crucial role in maintaining immune homeostasis and acts as a tumor suppressor. Its downregulation is associated with increased susceptibility to inflammation-driven diseases and cancer progression, making it a potential therapeutic target for autoimmune diseases, chronic inflammatory conditions, and certain cancers.
- Other names
- TIR8IL-1R8
02
Mechanism of action
Restores SIGIRR expression, leading to downstream effects on inflammation and cell proliferation
03
Biological functions
Negative regulation of inflammationInhibition of IL-1RI signalingInhibition of IL-18R signalingInhibition of ST2/IL-33 receptor signalingInhibition of TLR4 signalingInhibition of TLR7/8 signalingInhibition of TLR9 signalingInhibition of TLR3 signalingInhibition of TLR2/1 signalingSuppression of NF-κB pathwaySuppression of JNK MAP kinase pathwayRegulation of Th17 lymphocyte differentiation/proliferationmTOR pathway modulationImmune homeostasis
04
Disease associations
Autoimmune diseasesChronic inflammatory conditionsCancerChronic lymphocytic leukemiaRenal cell carcinoma
05
Safety considerations
Potential for broad immunosuppression if SIGIRR is excessively activatedNeed for careful titration to avoid unwanted side effects in anti-inflammatory therapies
06
Interacting drugs
Azacytidine (restores SIGIRR expression)
07
Biomarkers
SIGIRR expression levels (predictive of response to demethylating agents, cancer progression)
Beyond the preview
Go deeper on Interleukin-1 Receptor-like protein (SIGIRR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Interleukin-1 Receptor-like protein (SIGIRR).